Skip to main content
Equibles

PYPD · PolyPid Ltd.

Track PYPD — free

Use PYPD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PYPD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.27 +0.00 (+0.00%)
Rebalance outlook locked
Market Cap
$106.03M
Shares
20.31M
Volume · Sep 30 47.39K Avg daily vol (3M) 192.72K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$5.27 Open$5.27 Day$5.16–5.36 52W close$3.15–5.58 Avg vol 30d101K Short int130K · 0.6% float · 1.1d Short vol57% Last earningsAug 12, 2026 DataJun 2020–Sep 2026

Up next

Next earnings call
Nov 24, 2026 Est · unconfirmed · in 8 wks
Q1 2026 earnings call transcript
call held Apr 19, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+155.6%
Year over year · more shares
Price change (1Y)
+58.9%
Trailing year
Short interest
0.6%
Latest settlement · 1.1 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 16.3 · calm Equity put/call 0.53
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +14%
above
Price vs 50-day avg +7%
above
RSI (14) 53
neutral
MACD trend Negative
52-week position 87%
near high
Momentum
relative strength
Very Strong
1-month return −1%
trailing
6-month return +21%
trailing
YTD return +21%
this year
Relative strength +8%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $5 › 200d $5 — 50d above 200d
Institutional flow Accumulating
+65% holders QoQ · +13 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.64% of float · ▼ -33.2% MoM · 1.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
33 holders — near 3-yr high, broad support
Squeeze score 48
elevated · 0–100
Fundamentals
Poor
EPS growth −57%
Y/Y
Free cash flow $-28.1M
Quant / Vol
risk profile
Very High
Volatility 56%
annualized · 1-yr
Max drawdown −33%
past year
ATR 4.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+14% Bullish
Price vs 50-day avg
+7% Bullish
RSI (14)
53 Neutral
MACD trend
Negative Bearish
52-week position
87% Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $5 › 200d $5 — 50d above 200d
Institutional flow Accumulating
+65% holders QoQ · +13 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.64% of float · ▼ -33.2% MoM · 1.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
33 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $5 · 87% Range high $6
vs 200-day avg +14% vs 50-day avg +7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PYPD
PolyPid Ltd.
this stock
$106.03M +21.4% — — 0.6%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +15.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -1.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +553.0% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
33
% held
16.2%
Net QoQ
+168.7K sh
Top holder
AIGH Capital Management L…
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
130.4K
Days to cover
1.1d
Change
-64.6K sh
View
Short Volume
Short vol %
57%
As of
Sep 30, 2026
Short Total
View
Fails to Deliver
FTD shares
4.0K
Value
$21.2K
As of
Sep 3, 2026
View
Off-Exchange
Off-exchange %
54.6%
Week of
Aug 24, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-34.2M
EPS diluted
$2.09
View
Filings
SEC Filings
Latest
6-K
Filed
Aug 12, 2026
This year
12
View
Exempt Offerings
Offering
$26.7M
Filed
Jun 23, 2025
View
Earnings & Events
Earnings Calls
Last call
Sep 29, 2026
View
Investor Relations
Latest news
PolyPid Announces Participation i…
Published
Sep 15, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
PYPD +0.0% -1.1% +20.6% +2.5% +21.4%
SPY -0.7% +0.1% +12.2% -0.6% +11.8%
vs SPY +0.7% -1.2% +8.4% +3.1% +9.6%
Key facts CIK 1611842 CUSIP M8001Q126 13F (30d) 1 filings 1 filers Visit website Investor relations